PRRT plus holmium-166-SIRT (HEPAR PLuS) versus PRRT-only in patients with metastatic neuroendocrine tumors: A propensity-score matched analysis.

J Neuroendocrinol · 2025 · PMC12358199 · PMID 40302310

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

For more generic endpoints, the PFS 2y analysis showed a trend towards improvement, but no significant improvement in PFS and OS was demonstrated.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.